First biosimilar approved for macular degeneration, other eye conditions
Sep 23, 2021
Biosimilar to Lucentis approved to treat neovascular age-related macular degeneration, macular edema, myopic choroidal neovascularization
First biosimilar approved by FDA to treat common eye degeneration in elders
Sep 21, 2021
The Food and Drug Administration has approved a less expensive copy of the blockbuster drug Lucentis for treating age-related (wet) macular degeneration and several other eye conditions.
FDA approves first biosimilar insulin product
Jul 29, 2021
Semglee (insulin glargine-yfgn) is biosimilar to and interchangeable with Lantus (insulin glargine), provides cost-effective option
FDA OKs new insulin biosimilar for type 2 diabetes
Jul 30, 2021
Semglee is a safe and more cost-effective alternative to the drug Lantus (insulin glargine), the agency announced Wednesday. Semglee does not need a prescriber’s input to be substituted at the pharmacy.
FDA approves first biosimilar treatment
Apr 06, 2015
The Food and Drug Administration approved its first biosimilar product in March, opening the door for more costly drug alternatives.
FDA panel approves first biosimilar drug
Mar 10, 2015
The Food and Drug Administration approved its first biosimilar product last week, opening the door for more costly drug alternatives.